Medica Group PLC
Director / PDMR Shareholding
Medica Group PLC (the "Company") announces that on 4 July 2023, the PDMRs listed below had options that vested and were exercised due to the approval of Scheme of Arrangement via Court Sanction hearing. The exercised options were ordinary shares of 0.2p each in the Company under the Company's Performance Share Plan 2017, Deferred Bonus Plan 2017 and Save As You Earn Scheme:
| Name of PDMR | Number of shares subject to options | |
| Stuart Quin | | 744,671 |
| Richard Jones | | 545,399 |
| Kevin Terrins | | 284,292 |
| Sarah Burns | | 226,457 |
| Marc O'Brien Caroline Byrne Rob Lavis Fiona Carr | | 288,130 139,141 193,342 43,780 |
| Kim Scanlan | | 32,905 |
The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation, and set out more details of the transactions.
| 1. | Details of PDMR | |
| (a) | Name | 1. Stuart Quin 2. Richard Jones 3. Kevin Terrins 4. Sarah Burns 5. Marc O'Brien 6. Caroline Byrne 7. Rob Lavis 8. Fiona Carr 9. Kim Scanlan
|
| 2. | Reason for notification | |
| (b) | Position / status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Group Director of Corporate Development 4. Managing Director, UK 5. Chief Information Officer 6. Managing Director, Ireland 7. Group Medical Director 8. Group Head of Human Resources 9. Managing Director, US
|
| | Initial notification / amendment | Initial notification in each case |
| 3. | Details of the Issuer | |
| (a) | Name | Medica Group PLC |
| (b) | LEI | 213800B8XE5FUSZF5Z16 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted | |
| (a) | Description of the financial instrument | Ordinary shares of 0.2p each in the capital of the Company ("Shares") |
| (b) | Nature of the transaction | Vesting and exercise of options over Shares pursuant to the Company's Performance Share Plan 2017 |
| (c) | Price(s) and volume | £Nil Option Price in each case 1. 597,579 2. 454,832 3. 217,565 4. 175,869 5. 212,516 6. 85,323 7. 154,811 8. 37,141 9. 32,905
|
| (d) | Aggregated information | N/A |
| (e) | Date of the transaction | 4 July 2023 |
| (f) | Place of the transaction | Outside a trading venue |
| 1. | Details of PDMR | |
| (a) | Name | 1. Stuart Quin 2. Richard Jones 3. Kevin Terrins 4. Sarah Burns 5. Marc O'Brien 6. Caroline Byrne 7. Rob Lavis 8. Fiona Carr 9. Kim Scanlan
|
| 2. | Reason for notification | |
| (b) | Position / status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Group Director of Corporate Development 4. Managing Director, UK 5. Chief Information Officer 6. Managing Director, Ireland 7. Group Medical Director 8. Group Head of Human Resources 9. Managing Director, US
|
| | Initial notification / amendment | Initial notification in each case |
| 3. | Details of the Issuer | |
| (a) | Name | Medica Group PLC |
| (b) | LEI | 213800B8XE5FUSZF5Z16 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted | |
| (a) | Description of the financial instrument | Ordinary shares of 0.2p each in the capital of the Company ("Shares") |
| (b) | Nature of the transaction | Vesting and exercise of options over Shares pursuant to the Deferred Bonus Plan 2017 |
| (c) | Price(s) and volume | £Nil Option Price in each case 1. 129,092 2. 82,006 3. 48,727 4. 42,027 5. 57,614 6. 53,818 7. 35,107 8. 5,725 9. -
|
| (d) | Aggregated information | N/A |
| (e) | Date of the transaction | 4 July 2023 |
| (f) | Place of the transaction | Outside a trading venue |
| 1. | Details of PDMR | |
| (a) | Name | 1. Stuart Quin 2. Richard Jones 3. Kevin Terrins 4. Sarah Burns 5. Marc O'Brien 6. Caroline Byrne 7. Rob Lavis 8. Fiona Carr 9. Kim Scanlan
|
| 2. | Reason for notification | |
| (b) | Position / status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Group Director of Corporate Development 4. Managing Director, UK 5. Chief Information Officer 6. Managing Director, Ireland 7. Group Medical Director 8. Group Head of Human Resources 9. Managing Director, US
|
| | Initial notification / amendment | Initial notification in each case |
| 3. | Details of the Issuer | |
| (a) | Name | Medica Group PLC |
| (b) | LEI | 213800B8XE5FUSZF5Z16 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted | |
| (a) | Description of the financial instrument | Ordinary shares of 0.2p each in the capital of the Company ("Shares") |
| (b) | Nature of the transaction | Vesting and exercise of options over Shares pursuant to the Save As Your Earn Scheme 2020 |
| (c) | Price(s) and volume | £1.00 Option Price in each case 1. 18,000 2. - 3. 18,000 4. - 5. 18,000 6. - 7. - 8. - 9. -
|
| (d) | Aggregated information | N/A |
| (e) | Date of the transaction | 4 July 2023 |
| (f) | Place of the transaction | Outside a trading venue |
| 1. | Details of PDMR | |
| (a) | Name | 1. Stuart Quin 2. Richard Jones 3. Kevin Terrins 4. Sarah Burns 5. Marc O'Brien 6. Caroline Byrne 7. Rob Lavis 8. Fiona Carr 9. Kim Scanlan
|
| 2. | Reason for notification | |
| (b) | Position / status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Group Director of Corporate Development 4. Managing Director, UK 5. Chief Information Officer 6. Managing Director, Ireland 7. Group Medical Director 8. Group Head of Human Resources 9. Managing Director, US
|
| | Initial notification / amendment | Initial notification in each case |
| 3. | Details of the Issuer | |
| (a) | Name | Medica Group PLC |
| (b) | LEI | 213800B8XE5FUSZF5Z16 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted | |
| (a) | Description of the financial instrument | Ordinary shares of 0.2p each in the capital of the Company ("Shares") |
| (b) | Nature of the transaction | Vesting and exercise of options over Shares pursuant to the Save As Your Earn Scheme 2021 |
| (c) | Price(s) and volume | £1.46 Option Price in each case 1. - 2. 8,561 3. - 4. 8,561 5. - 6. - 7. 3,424 8. - 9. -
|
| (d) | Aggregated information | N/A |
| (e) | Date of the transaction | 4 July 2023 |
| (f) | Place of the transaction | Outside a trading venue |
| 1. | Details of PDMR | |
| (a) | Name | 1. Stuart Quin 2. Richard Jones 3. Kevin Terrins 4. Sarah Burns 5. Marc O'Brien 6. Caroline Byrne 7. Rob Lavis 8. Fiona Carr 9. Kim Scanlan
|
| 2. | Reason for notification | |
| (b) | Position / status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Group Director of Corporate Development 4. Managing Director, UK 5. Chief Information Officer 6. Managing Director, Ireland 7. Group Medical Director 8. Group Head of Human Resources 9. Managing Director, US
|
| | Initial notification / amendment | Initial notification in each case |
| 3. | Details of the Issuer | |
| (a) | Name | Medica Group PLC |
| (b) | LEI | 213800B8XE5FUSZF5Z16 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted | |
| (a) | Description of the financial instrument | Ordinary shares of 0.2p each in the capital of the Company ("Shares") |
| (b) | Nature of the transaction | Vesting and exercise of options over Shares pursuant to the Save As Your Earn Scheme 2022 |
| (c) | Price(s) and volume | £1.422 Option Price in each case 1. - 2. - 3. - 4. - 5. - 6. - 7. - 8. 914 9. -
|
| (d) | Aggregated information | N/A |
| (e) | Date of the transaction | 4 July 2023 |
| (f) | Place of the transaction | Outside a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.